Locus Biosciences Announces $35 Million Financing

May 18, 2022•over 3 years ago

Amount Raised

$35 Million

San Francisco

Description

Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note. Notable investors participating in the round included Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson and Johnson Innovation

Company Information

Company

Locus

Location

San Francisco, California, United States

About

Locus is a technology platform that uses machine learning and proprietary algorithms to automate complex supply chain decisions. Its smart supply chain solutions provide end-to-end visibility and enable enterprises to enhance their operational efficiency by reining costs, streamlining the customer experience, and reducing environmental impact. Locus' scalable solutions include route optimization, real-time tracking and analytics, sales beat optimization, territory planning, vehicle allocation and network design. Our future-ready platform has resulted in $150 million+ savings in logistics costs, 70 million+ kilometer reductions in distance traveled, and 17 million+ kilograms reduction in GHG emissions across clients like Nestle, Mondelez, Unilever, BigBasket, Bluedart, Bukalapak, The Tata Group, and many others. The company powers deliveries across North America, Europe, Southeast Asia, Middle East, ANZ, and the Indian Subcontinent. Visit www.locus.sh to know more or follow us on LinkedIn!

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech